<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02648659</url>
  </required_header>
  <id_info>
    <org_study_id>KNUMC-JSW-ILA01</org_study_id>
    <nct_id>NCT02648659</nct_id>
  </id_info>
  <brief_title>The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in H.Pylori Patients</brief_title>
  <official_title>The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in Helicobacter Pylori Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyungpook National University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assessed the effect of tailored eradication therapy according to Clarithromycin
      resistance in Helicobacter pylori patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study assessed the effect of tailored eradication therapy according to Clarithromycin
      resistance in Helicobacter pylori patients.

      The patients with gastric or duodenal ulcer by endoscopy were registered at the study and
      inspected Rapid Urease test, Biopsy, IgG-Hp antibody.

      The tailored eradication therapy was prescribed to patients that confirmed Helicobacter
      pylori positive in two or more of among the three tests for 14 days. Through this, This study
      is to assess the effectiveness of eradication rate and to evaluate safety and tolerability of
      Ilaprazole 10mg qid treatment
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2, 2016</start_date>
  <completion_date type="Actual">February 14, 2017</completion_date>
  <primary_completion_date type="Actual">January 6, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate after tailored therapy assessed by urea breath test</measure>
    <time_frame>Test at 4 -6 weeks after completion of medication</time_frame>
    <description>After completion of 14days tailored therapy, the participants will be followed at 4-6 weeks with urea breath test (UBT). The eradication rate will be assessed by the result of UBT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by questionnaire</measure>
    <time_frame>Questionnaire and diary during medication for 14days</time_frame>
    <description>During the medication of tailored therapy, the participants will be asked to check the compliance and adverse events with diary and questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Peptic Ulcer</condition>
  <arm_group>
    <arm_group_label>Ilaprazole + Amoxicillin + Clarithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ilaprazole 10mg qid, Amoxicillin 500mg qid, Clarithromycin bid for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ilaprazole + Amoxicillin + Metronidazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ilaprazole 10mg qid, Amoxicillin 500mg qid, Metronidazole 500mg tid for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ilaprazole + Amoxicillin + Clarithromycin + Metronidazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ilaprazole 10mg qid, Amoxicillin 500mg qid, Clarithromycin 500mg bid, Metronidazole 500mg tid for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ilaprazole</intervention_name>
    <description>Ilaprazole 10mg 1tablet qid(4 times/day)</description>
    <arm_group_label>Ilaprazole + Amoxicillin + Clarithromycin</arm_group_label>
    <arm_group_label>Ilaprazole + Amoxicillin + Metronidazole</arm_group_label>
    <arm_group_label>Ilaprazole + Amoxicillin + Clarithromycin + Metronidazole</arm_group_label>
    <other_name>Noltec®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Amoxicillin 500mg 1capsule qid(4times/day)</description>
    <arm_group_label>Ilaprazole + Amoxicillin + Clarithromycin</arm_group_label>
    <arm_group_label>Ilaprazole + Amoxicillin + Metronidazole</arm_group_label>
    <arm_group_label>Ilaprazole + Amoxicillin + Clarithromycin + Metronidazole</arm_group_label>
    <other_name>Pamoxin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Clarithromycin 500mg 1tablet bid(2times/day)</description>
    <arm_group_label>Ilaprazole + Amoxicillin + Clarithromycin</arm_group_label>
    <arm_group_label>Ilaprazole + Amoxicillin + Clarithromycin + Metronidazole</arm_group_label>
    <other_name>Clafaxin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Metronidazole 250mg 2tablets tid(3times/day)</description>
    <arm_group_label>Ilaprazole + Amoxicillin + Metronidazole</arm_group_label>
    <arm_group_label>Ilaprazole + Amoxicillin + Clarithromycin + Metronidazole</arm_group_label>
    <other_name>Flasinyl®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • 20 year old ≤ Male or female &lt; 80 year old

               -  Among Patients with gastric or duodenal ulcer by endoscopy, Subject who is
                  identified Helicobacter pylori-positive in the conduct of two or more of the
                  following tests ; Rapid Urease test, Biopsy test, IgG-Hp antibody test.

               -  Subject who fully understands conditions of clinical trial

               -  Subject who agrees to participate and spontaneously sign the ICF

        Exclusion Criteria:

          -  Known hypersensitivity to experimental and concomitant drugs

          -  Subjects who are taking contraindicated medications for experimental and concomitant
             drug.

          -  Subjects with abnormal levels in the laboratory tests

               -  Total Bilirubin, Creatinine&gt; 1.5 times upper limit of normal

               -  AST, ALT, Alkaline phosphatase, BUN&gt; 2 times upper limit of normal

          -  Administrated of PPI, antibiotic medication within 2 weeks prior to commencement of
             the study.

          -  Pregnant and/or lactating women

          -  Reproductive aged women not using contraception

          -  Uncontrolled diabetics

          -  Uncontrolled hypertension

          -  Uncontrolled liver dysfunction

          -  Alcoholics

          -  Subjects with a history or possibility of digestive malignancy within 5 years

          -  Subjects with a history of gastrectomy or esophagectomy

          -  Subjects with hereditary diseases such as Galactose intolerance, Lapp lactose
             deficiency, glucose-galactose malabsorption

          -  Subjects participating in a clinical trial before another trial within 30 days

          -  Inconsistence judged subject by researcher
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seong Woo Jeon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook national university medical center</affiliation>
  </overall_official>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <last_update_submitted>February 19, 2017</last_update_submitted>
  <last_update_submitted_qc>February 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyungpook National University</investigator_affiliation>
    <investigator_full_name>Seong Woo Jeon</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peptic Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

